Lynx Announces Gene Expression Analysis Deal With AstraZeneca

Apr 04, 2001, 01:00 ET from Lynx Therapeutics, Inc.

    HAYWARD, Calif., April 4 /PRNewswire/ --
 Lynx Therapeutics, Inc. (Nasdaq:   LYNX) announced today a collaborative
 research agreement with AstraZeneca (NYSE:   AZN; FTSE: AZN; Stockholm: AZN) to
 identify genes that are differentially expressed between different human
 tissues.  This is the second agreement signed between Lynx and AstraZeneca in
 2001.
     AstraZeneca will provide DNA samples from certain human tissues, which
 Lynx will analyze using its Megasort(TM) technology. The differences in the
 gene expression patterns are expected to provide important information on the
 physiological processes leading to diseases or conditions involving these
 tissue types.  Under the terms of the agreement, Lynx will receive payments
 from AstraZeneca upon achievement of certain project objectives. No other
 financial terms of the agreement were disclosed.
     "We are delighted to announce our second collaboration with AstraZeneca,"
 stated Dr. Norrie Russell, President and Chief Executive Officer of Lynx. "We
 believe that the application of Megasort(TM) technology toward the discovery
 of differentially expressed genes provides a powerful and comprehensive
 approach to understanding the physiological pathways underlying disease."
     "We are looking forward to a successful collaboration using Lynx
 technology to enhance our capability to identify changes in gene expression
 profiles in different tissues and disease states. Such information now plays a
 key role in drug discovery," said Dr. John Stageman, Vice President, Global
 Enabling Science and Technology, AstraZeneca.
 
     About Megasort(TM) Technology
     Megasort(TM) technology provides a method to identify and physically
 extract essentially all genes that differ in expression levels between two
 samples.  Megasort(TM) technology compares two DNA samples, each containing
 millions of molecules, and extracts those DNA molecules that are present in
 different proportions in the samples.  Because the comparison and sorting
 process requires no prior knowledge of the sequences of the genes in either
 sample, Megasort(TM) technology can be used with samples isolated from tissues
 or organisms that are not well characterized.
 
     About the Companies
     AstraZeneca is a major international healthcare business engaged in the
 research, development, manufacture and marketing of ethical (prescription)
 pharmaceuticals and the supply of healthcare services. It is one of the top
 five pharmaceutical companies in the world with healthcare sales of
 $15.8 billion and leading positions in cardiovascular, gastrointestinal,
 oncology, anaesthesia including pain management, central nervous system (CNS)
 and respiratory products.
 
     Lynx is a leader in the development and application of novel technologies
 for the discovery of gene expression patterns and genomic variations important
 to the pharmaceutical, biotechnology and agricultural industries. These
 approaches are based on Megaclone(TM) technology, Lynx's unique and
 proprietary cloning procedure, which transforms a sample containing millions
 of DNA molecules into one made up of millions of micro-beads, each of which
 (referred to as a DNA analysis template) carries approximately 100,000 copies
 of one of the DNA molecules in the sample. Lynx prepares nearly 100 million of
 such DNA analysis templates every week for subsequent analyses.  Megaclone(TM)
 technology is the foundation for Lynx's analytical applications, including:
 Massively Parallel Signature Sequencing, or MPSS(TM), technology, which
 provides gene sequence information and high-resolution gene expression data
 including even the very rare transcripts; Megasort(TM) technology, which
 provides differentially expressed gene sets; and Megatype(TM) technology,
 which is expected to provide single nucleotide polymorphism, or SNP,
 disease- or trait-association information.  For more information, please visit
 http://www.lynxgen.com.
 
     Statements included in this press release that are not historical in
 nature are "forward-looking statements" within the meaning of the "safe
 harbor" provisions of the Private Securities Litigation Reform Act of 1995.
 These statements include those related to the identification of differentially
 expressed genes, as well as the potential success of collaboration
 arrangements.  Lynx cautions readers that forward-looking statements are
 subject to certain risks and uncertainties that could cause actual results to
 differ materially from those indicated in the forward-looking statements.
 These risks and uncertainties can include the failure to discover any product
 candidates as a result of the collaboration; the possible failure of any
 clinical trials for product candidates that arise from the collaboration; the
 inability to successfully market products; Lynx's inability to identify
 differentially expressed genes; the prospect of continued losses by Lynx; and
 other risks identified from time to time in Lynx's reports filed with the U.S.
 Securities and Exchange Commission.  Lynx directs readers to its reports filed
 with the U.S. Securities and Exchange Commission, including its Annual Report
 on Form 10-K for the year ended December 31, 2000.  The information in this
 press release is current as of its release date.  Lynx takes no responsibility
 to update the information.
 
 

SOURCE Lynx Therapeutics, Inc.
    HAYWARD, Calif., April 4 /PRNewswire/ --
 Lynx Therapeutics, Inc. (Nasdaq:   LYNX) announced today a collaborative
 research agreement with AstraZeneca (NYSE:   AZN; FTSE: AZN; Stockholm: AZN) to
 identify genes that are differentially expressed between different human
 tissues.  This is the second agreement signed between Lynx and AstraZeneca in
 2001.
     AstraZeneca will provide DNA samples from certain human tissues, which
 Lynx will analyze using its Megasort(TM) technology. The differences in the
 gene expression patterns are expected to provide important information on the
 physiological processes leading to diseases or conditions involving these
 tissue types.  Under the terms of the agreement, Lynx will receive payments
 from AstraZeneca upon achievement of certain project objectives. No other
 financial terms of the agreement were disclosed.
     "We are delighted to announce our second collaboration with AstraZeneca,"
 stated Dr. Norrie Russell, President and Chief Executive Officer of Lynx. "We
 believe that the application of Megasort(TM) technology toward the discovery
 of differentially expressed genes provides a powerful and comprehensive
 approach to understanding the physiological pathways underlying disease."
     "We are looking forward to a successful collaboration using Lynx
 technology to enhance our capability to identify changes in gene expression
 profiles in different tissues and disease states. Such information now plays a
 key role in drug discovery," said Dr. John Stageman, Vice President, Global
 Enabling Science and Technology, AstraZeneca.
 
     About Megasort(TM) Technology
     Megasort(TM) technology provides a method to identify and physically
 extract essentially all genes that differ in expression levels between two
 samples.  Megasort(TM) technology compares two DNA samples, each containing
 millions of molecules, and extracts those DNA molecules that are present in
 different proportions in the samples.  Because the comparison and sorting
 process requires no prior knowledge of the sequences of the genes in either
 sample, Megasort(TM) technology can be used with samples isolated from tissues
 or organisms that are not well characterized.
 
     About the Companies
     AstraZeneca is a major international healthcare business engaged in the
 research, development, manufacture and marketing of ethical (prescription)
 pharmaceuticals and the supply of healthcare services. It is one of the top
 five pharmaceutical companies in the world with healthcare sales of
 $15.8 billion and leading positions in cardiovascular, gastrointestinal,
 oncology, anaesthesia including pain management, central nervous system (CNS)
 and respiratory products.
 
     Lynx is a leader in the development and application of novel technologies
 for the discovery of gene expression patterns and genomic variations important
 to the pharmaceutical, biotechnology and agricultural industries. These
 approaches are based on Megaclone(TM) technology, Lynx's unique and
 proprietary cloning procedure, which transforms a sample containing millions
 of DNA molecules into one made up of millions of micro-beads, each of which
 (referred to as a DNA analysis template) carries approximately 100,000 copies
 of one of the DNA molecules in the sample. Lynx prepares nearly 100 million of
 such DNA analysis templates every week for subsequent analyses.  Megaclone(TM)
 technology is the foundation for Lynx's analytical applications, including:
 Massively Parallel Signature Sequencing, or MPSS(TM), technology, which
 provides gene sequence information and high-resolution gene expression data
 including even the very rare transcripts; Megasort(TM) technology, which
 provides differentially expressed gene sets; and Megatype(TM) technology,
 which is expected to provide single nucleotide polymorphism, or SNP,
 disease- or trait-association information.  For more information, please visit
 http://www.lynxgen.com.
 
     Statements included in this press release that are not historical in
 nature are "forward-looking statements" within the meaning of the "safe
 harbor" provisions of the Private Securities Litigation Reform Act of 1995.
 These statements include those related to the identification of differentially
 expressed genes, as well as the potential success of collaboration
 arrangements.  Lynx cautions readers that forward-looking statements are
 subject to certain risks and uncertainties that could cause actual results to
 differ materially from those indicated in the forward-looking statements.
 These risks and uncertainties can include the failure to discover any product
 candidates as a result of the collaboration; the possible failure of any
 clinical trials for product candidates that arise from the collaboration; the
 inability to successfully market products; Lynx's inability to identify
 differentially expressed genes; the prospect of continued losses by Lynx; and
 other risks identified from time to time in Lynx's reports filed with the U.S.
 Securities and Exchange Commission.  Lynx directs readers to its reports filed
 with the U.S. Securities and Exchange Commission, including its Annual Report
 on Form 10-K for the year ended December 31, 2000.  The information in this
 press release is current as of its release date.  Lynx takes no responsibility
 to update the information.
 
 SOURCE  Lynx Therapeutics, Inc.